Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Competition Body Backs Up Claim That Pfizer & Flynn Abused Dominant Position With ‘Excessive’ Prices

Executive Summary

The UK CMA has explained why it believes Pfizer and Flynn Pharma abused a dominant market position by charging “excessive and unfair” prices for a generic epilepsy drug, while the two companies have laid out their the grounds for appealing against the decision.

Advertisement

Related Content

UK Fine For Pfizer/Flynn’s ‘Excessive And Unfair’ Pricing Sends Clear Message To Others

Topics

Advertisement
UsernamePublicRestriction

Register

PS120889

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel